IP Library Granted Patent US 12,209,060
Granted Patent B2
US 12,209,060 · App. 17/878,174 · Granted Jan 28, 2025

Ketamine derivatives and compositions thereof

Inventors: Jia-Ning Xiang (Fremont, CA); Xuesong Xu (Fremont, CA); Hao-Wei Shih (New Taipei, TW); Wai-Si Eng (Maple Glen, PA)
Assignee: XWPHARMA LTD.
C07C271/24A61K9/0053A61K31/165A61K31/166C07C211/35C07C271/56C07D213/80C07D305/06C07D309/08C07D317/68C07D207/16C07D207/28C07D211/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,060
App. No.
17/878,174
Granted
Jan 28, 2025
Kind
B2
Abstract

Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.

Claims (39)

1. A compound of Formula (1):

or a pharmaceutically acceptable salt thereof, wherein,

R 1 is selected from hydrogen and C 1-6 alkyl; and

R 2 is a moiety of Formula (6):

wherein,

p is an integer from 1 to 3; and

each R 8 is independently selected from hydrogen, C 1-6 alkyl, and —NH 2 .

2. The compound of claim 1 , wherein p is 1.

3. The compound of claim 1 , wherein R 8 is hydrogen.

4. The compound of claim 1 , wherein R 8 is C 1-6 alkyl.

5. The compound of claim 1 , wherein R 8 is methyl.

6. The compound of claim 1 , wherein R 8 is —NH 2 .

7. The compound of claim 1 , wherein p is 1; and R 8 is hydrogen.

8. The compound of claim 1 , wherein p is 1; and R 8 is C 1-6 alkyl.

9. The compound of claim 1 , wherein p is 1; and R 8 is methyl.

10. The compound of claim 1 , wherein p is 1; and R 8 is —NH 2 .

11. The compound of claim 1 , wherein the compound is the (R)-isomer having the structure of Formula (1a):

12. The compound of claim 1 , wherein the compound is the(S)-isomer having the structure of Formula (1b):

13. The compound of claim 1 , wherein the compound is selected from:

1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy) ethyl nicotinate (14);

(s)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 6-methylnicotinate (29);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 4-methylnicotinate (54);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-methylnicotinate (55);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 6-methylnicotinate (56);

(S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-aminonicotinate (61);

(R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl nicotinate (67);

(R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-aminonicotinate (73); and

a pharmaceutically acceptable salt of any of the foregoing.

14. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition comprises an oral dosage form.

16. A method of providing a therapeutically effective concentration of (R)-ketamine, (S)-ketamine, a metabolite of any of the foregoing, or a combination of any of the foregoing in a patient's blood comprising administering to a patient, a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

17. The method of claim 16 , wherein administering comprises orally administering.

18. A method of treating depression in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

19. The method of claim 18 , wherein administering comprises orally administering.

20. A method of treating pain in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

21. The method of claim 20 , wherein administering comprises orally administering.

22. The method of claim 20 , wherein the pain is selected from back pain, cancer pain, carpal tunnel syndrome pain, chronic pain, pain associated with diabetic peripheral neuropathy, pain associated with fibromyalgia, pain associated with migraine, myofascial pain, neuropathic pain, neuralgia, pain associated with osteoarthritis, pain associated with peripheral neuropathy, postoperative pain, regional pain syndrome, rheumatoid arthritis pain, sciatica, scoliosis pain, spinal cord injury pain, pain associated with spinal stenosis, trigeminal neuralgia, and traumatic pain.

23. A method of treating a psychiatric disease in a patient comprising administering to a patient in need of such treatment, a therapeutically effective amount of the compound of claim 1 , wherein the psychiatric disease or disorder is selected from an alcohol use disorder, an anxiety disorder, an obsessive-compulsive disorder, an opioid use disorder, and a posttraumatic stress disorder.

24. The method of claim 23 , wherein administering comprises orally administering.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2022
From: XIANG, JIA-NING; XU, XUESONG; SHIH, HAO-WEI; ENG, WAI-SI
To: XWPHARMA LTD.
Reel/Frame 060683/0092 →
Continuity (6)
Continuation 17067968 · Oct 12, 2020
Continuation 16838633 · Apr 2, 2020
Division 16502562 · Jul 3, 2019
Continuation PCTCN2019070912 · Jan 8, 2019
Provisional Application 62615948 · Jan 10, 2018
Related Publication 20220411365A1 · Dec 29, 2022
References Cited (66)
US 5648087A · Ovaert et al. · 1997 [cited by applicant]
US 5837730A · Javitt · 1998 [cited by applicant]
US 6248789B1 · Weg · 2001 [cited by applicant]
US 11110070B2 · Brachman et al. · 2021 [cited by applicant]
US 20040248964A1 · Crooks · 2004 [cited by examiner]
US 20080268071A1 · Gant et al. · 2008 [cited by applicant]
US 20130237559A1 · Ortiz et al. · 2013 [cited by applicant]
US 20140079740A1 · Salama · 2014 [cited by applicant]
US 20150259277A1 · Sleigh et al. · 2015 [cited by applicant]
US 20180098993A1 · Wainer et al. · 2018 [cited by applicant]
US 20180177744A1 · Jay · 2018 [cited by applicant]
US 20180289637A1 · Laufer et al. · 2018 [cited by applicant]
US 20190240184A1 · Hashimoto · 2019 [cited by applicant]
US 20190322618A1 · Xiang et al. · 2019 [cited by applicant]
US 20200306194A1 · Glue et al. · 2020 [cited by applicant]
CN 104395283 · 2015 [cited by applicant]
CN 111836798 · 2020 [cited by applicant]
EA 201590697 · 2015 [cited by applicant]
JP 2006510618 · 2006 [cited by applicant]
JP 2009509982 · 2009 [cited by applicant]
JP 2015501302 · 2015 [cited by applicant]
JP 2015535847 · 2015 [cited by applicant]
WO 9707750 · 1997 [cited by applicant]
WO 2004045601 · 2004 [cited by applicant]
WO 2008134525 · 2008 [cited by applicant]
WO 2011109799 · 2011 [cited by applicant]
WO 2013019561 · 2013 [cited by applicant]
WO 2013056229 · 2013 [cited by applicant]
WO 2013170068 · 2013 [cited by applicant]
WO 2014057414 · 2014 [cited by applicant]
WO 2014205389 · 2014 [cited by applicant]
WO 2014205393 · 2014 [cited by applicant]
WO 2017087388 · 2017 [cited by applicant]
WO 2017117529 · 2017 [cited by applicant]
WO 2017180589A1 · 2017 [cited by applicant]
WO 2017208031 · 2017 [cited by applicant]
WO 2018079693 · 2018 [cited by applicant]
WO 2018234568A2 · 2018 [cited by applicant]
WO 2019137381A1 · 2019 [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2018/090151, mailed on Feb. 20, 2019, 14 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2019/070912, mailed on Mar. 27, 2019, 11 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2019/090189, mailed on Sep. 18, 2019, 15 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2019/095144, mailed on Sep. 26, 2019, 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/502,562, mailed on Nov. 5, 2019, 42 pages. [cited by applicant]
Registry RN 1430202-54-2, Oct. 21, 2013. [cited by applicant]
Dakwar et al., “A Single Ketamine Infusion Combined with Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial”, American Journal Psychiatry, Feb. 2020, vol. 177, No. 2… [cited by applicant]
Dimitrov et al., “Ketamine esters and amides as short-acting anaesthetics: Structure-activity relationships for the side-chain”, Bioorganic & Medicinal Chemistry, 2019, vol. 27, pp. 1226-1231. [cited by applicant]
Ebert et al., “Norketamine, the main metabolite of ketamine, in a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord”, European Journal of Pharmacology, 1997, vol. 333, p. 99-104. [cited by applicant]
Fawcett et al., “Anxiety Syndromes and Their Relationship to Depressive Illness”, Journal of Clinical Psychiatry, 1983, vol. 44, p. 8-11. [cited by applicant]
Feder et al., “Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Clinical Trial”, JAMA Psychiatry, vol. 71, No. 6, 2014, p. 681-688. [cited by applicant]
Feder et al., “A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder”, American Journal of Psychiatry, Feb. 2021, vol. 178, No. 2, pp. 193-202. [cited by applicant]
Jose, J. et al., “Structure-activity relationships for ketamine esters as short-acting anaesthetics”, Bioorganic & Medicinal Chemistry, Sep. 2013, vol. 21, Issue 17, p. 5098-5106. [cited by applicant]
Lahti et al., “Ketamine activates psychosis and alters limbic blood flow in schizophrenia”, Clinical Neuroscience and Neuropathy, NeuroReport, 1995, vol. 6, p. 869-872. [cited by applicant]
Liriano et al., “Ketamine as treatment for post-traumatic stress disorder: a review”, Drugs in Context, 3:212305, 2019, pp. 1-7. [cited by applicant]
Mayo Clinic, Depression (major depressive disorder), Mayo Foundation for Medical Education and Research, 1998-2021, 5 pages. [cited by applicant]
Mollaahmetoglu et al., “This Is Something That Changed My Life: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders”, Frontiers in Psychiatry, Aug. 2021, vol.… [cited by applicant]
Morgan et al., “Is Persistent Ketamine Use a Valid Model of the Cognitive and Ocular Deficits in Schizophrenia?”, Biol Psychiatry, 2009, vol. 65, p. 1099-1102. [cited by applicant]
Nielsen et al., “Intraoperative S-ketamine for the reduction of opioid consumption and pain one year after spine surgery: A randomized clinical trial of opioid-dependent patients”, Eur J Pain, Jul. 2018, 2019, vol. 23, … [cited by applicant]
Rodriguez et al., “Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept”, Neuropsychopharmacology, 2013, vol. 38, p. 2475-2483. [cited by applicant]
Sanacora et al., “A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorder”, JAMA Psychiatry , Clinical Review and Education Special Communication, 2017, 24 pages. [cited by applicant]
Search Report for Australia Application No. 2019206950, mailed on Oct. 26, 2020, 7 pages. [cited by applicant]
Search Report for Russia Application No. 2020126393 mailed on Dec. 1, 2020, 2 pages. [cited by applicant]
Search Report and Written Opinion for Singapore Application No. 11202006575T, mailed on Oct. 4, 2021, 12 pages. [cited by applicant]
Taylor et al., “Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial”, Neuropsychopharmacology, 2018, vol. 43, p. 325-333. [cited by applicant]
Zhao et al., “Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression”, British Journal of Clinical Pharmacology, 2012, vol. 74, … [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/040217, mailed on Nov. 30, 2022, 14 pages. [cited by applicant]